Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors

GA Gusarova, AG Turkina

Hematology Research Center, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Galina Anatol’evna Gusarova, PhD, 4а Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; Tel: +7(495)612-16-36; e-mail: galina1966@bk.ru

For citation: Gusarova GA, Turkina AG. Arterial Events in Patients with Chronic Myeloid Leukemia Receiving Treatment with Second Generation Tyrosine Kinase Inhibitors. Clinical oncohematology. 2016;9(4):474–84 (In Russ).

DOI: 10.21320/2500-2139-2016-9-4-474-484


ABSTRACT

Target therapy of chronic myeloid leukemia (CML) by tyrosine kinase inhibitors (TKI) allows to achieve high rates of the overall survival in CML. The choice of TKI treatment in every particular case should be based on individual CML patient’s characteristics, including comorbidities and the risk of adverse events (AE). Every TKI has a particular toxicity profile depending on off-target action spectrum. A probability of arterial AEs on TKI therapy is comparatively low but they may be life threatening. It is highly important to evaluate this kind of AEs during a long period of vascular TKI exposure. The age-specific increased incidence of cardiovascular and respiratory diseases is an additional factor in these patients with high overall survival on TKI therapy. The article is devoted to the analysis of frequency, mechanisms, particular features, methods of diagnostics and treatment of arterial AEs emerging on second generation TKI (nilotinib and dasatinib) therapy. The detailed characteristics of arterial occlusive events on nilotinib therapy and pulmonary arterial hypertension on dasatinib are presented. Special attention is paid to the analysis of risk factors of vascular AEs and the ways to correct modified risk factors. Timely assessment of clinical symptoms of cardiopulmonary, ischemic diseases/complications, and metabolic disorders helps to find specialized medical care (by a cardiologist, pulmonologist, endocrinologist), to prescribe an adequate therapy, provide prevention of complications and make decision about TKI dose adjustment/switching to alternative TKI being a true foundation of safe personalized treatment in CML patients.


Keywords: tyrosine kinase inhibitors, artery occlusion, atherosclerosis, pulmonary hypertension.

Received: May 24, 2016

Accepted: June 16, 2016

Read in PDF (RUS)pdficon

REFERENCES

  1. Hochhaus A, O’Brien SC, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054–61. doi: 10.1038/leu.2009.38.
  2. Martinelli G, Soverini S, Rosti G, et al. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica. 2005;90:534–41.
  3. Deiniger MW. Optimizing therapy of chronic myeloid leukemia. Exp Hematol. 2007;35(4):144–54. doi: 10.1016/j.exphem.2007.01.023.
  4. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiling of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal different interaction networks and novel kinase and non-kinase targets. Blood. 2007;110(12):4055–63. doi: 10.1182/blood-2007-07-102061.
  5. Drueckes P, Fendrich G, Furet P, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2010;1804(3):445–53. doi: 10.1016/j.bbapap.2009.11.008.
  6. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. 2011;117(4):1141–5. doi: 10.1182/blood-2010-03-277152.
  7. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–70. doi: 10.1056/nejmoa0912614.
  8. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542–51. doi: 10.1056/nejmoa055104.
  9. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy. Am J Hematol. 2011;86(7):533–9. doi: 10.1002/ajh.22037.
  10. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86(7):610–1. doi: 10.1002/ajh.22051.
  11. Quintas-Gardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymph Myel Leuk. 2012;12(5):337–40. doi: 1016/j.clml.2012.04.005.
  12. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004. doi: 10.1056/nejmoa022457.
  13. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly-diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28(3):424–30. doi: 10.1200/jco.2009.25.3724.
  14. Giles FG, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27(6):1310–5. doi: 10.1038/leu.2013.69.
  15. Le Coutre P, Rea D, Abruzzese H, et al. Severe peripheral artery disease during nilotinib therapy. J Natl Cancer Inst. 2011;103(17):1347–8. doi: 10.1093/jnci/djr292.
  16. Schwarz M, Kim TD, Mirault N, et al. Elevated risk of peripheral artery occlusive disease (PAOD) in nilotinib treated chronic phase chronic myeloid leukemia (CML) patients assessed by ankle-brachial-index (ABI) and duplex ultrasonography. 54 ASH Meeting and Exposition. 2012: abstract 914.
  17. Saglio G, Hochhaus, Huges TP, et al. ENESTnd Update: nilotinib (NIL) vs imatinib (IM) in patients (PTS) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomes. Blood. 2013;122(21): Abstract 92.
  18. Hadzijusufovic E, Albrect-Schgoer K, Huber K, et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potentional explanation for drug-induced vasculopathy in CML. Blood. 2013;122(12): Abstract 257.
  19. Rea D, Mirault T, Raffoux E, et al. Peripheral arterial occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib. Blood. 2013;122(21): Abstract 4018.
  20. Larson RA, Kim D-W, Jootar S, et al. ENESTnd 5 years (y) update: long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM). J Clin Oncol. 2014;32(5s): Abstract 7073.
  21. Cortes JE, Saglio G, Baccarani M, et al. Final study results of the phase 3 Dasatinib versus Imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA 180-056). Blood. 2014;124(21):152.
  22. Hehlmann R, Lauseker M, Schreiber A, et al. Adverse events (AE) under imatinib treatment over 10 years: results from 1501 patients of the randomized CML-study IV. Blood. 2013;122(12): Abstract 4012.
  23. Lassila M. Imatinib attenuates diabetes-associates atherosclerosis. Atheroscler Tromb Vasc Biol. 2014;24(5):935–42. doi: 10.1161/01.atv.0000124105.39900.db.
  24. Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2nd generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Hematologica. 2014;99(7):1197–203. doi: 10.3324/haematol.2014.104075.
  25. Britto K, Wong E, Hou G, et al. Discoidin domain receptor 1 on bone marrow-derived cells promotes macrophage accumulation during atherogenesis. Circ Res. 2009;105(11):1141–8. doi: 10.1161/circresaha.109.207357.
  26. Franco C, Ahmad PJ, Hou G, et al. Increased cell and matrix accumulation during atherogenesis in mice with vessel wall-specific deletion of discoidin domain receptor 1. Circ Res. 2010;106(11):1775–83. doi: 10.1161/circresaha.109.213637.
  27. Breccia M, Muscaritoli M, Gentilini F, et al. Impaired fasting glucose level as metabolic effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res. 2007;31(12):1770–2. doi: 10.1016/j.leukres.2007.01.024.
  28. Крюков Н.Н., Николаевский Е.Н., Поляков В.П. Ишемическая болезнь сердца (Современные аспекты клиники, диагностики, лечения). Самара, 2010. 651 с. [Kryukov NN, Nikolaevskii EN, Polyakov VP. Ishemicheskaya bolezn’ serdtsa (Sovremennye aspekty kliniki, diagnostiki, lecheniya) (Coronary artery disease (Current aspects of clinical presentation, diagnosis, and treatment).) Samara; 2010. 651 p. (In Russ)]
  29. Pennywell DJ, Tan T-Z, Zhang WW. Optimal management of infrainguinal arterial occlusive disease. Vasc Health Risk Manag. 2014;10:599–608. doi: 10.2147/vhrm.s50779.
  30. Национальное общество по изучению атеросклероза (НОА), Российское кардиологическое общество (РКО), Российское общество кардиосоматической реабилитации и вторичной профилактики (РосОКР). Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, V пересмотр. М., 2012. [National Society of Atherosclerosis (NSA), Russian Cardiological Society (RCS), Russian Society of Cardiosomatic Rehabilitation and Secondary Prophylaxis (RSCR). Diagnosis and treatment of lipid metabolism impairment for prevention and treatment of atherosclerosis. National Guidelines, V edition. Moscow; 2012. (In Russ)]
  31. Мамедова Н.М., Чепурина Н.А. Суммарный сердечно-сосудистый риск: от теории к практике. Пособие для врачей. М., 2007. [Mamedova NM, Chepurina NA. Summarnyi serdechno-sosudistyi risk: ot teorii k praktike. Posobie dlya vrachei. (Overall cardiovascular risk: from theory to practice.) Moscow; 2007. (In Russ)]
  32. Valent P, Hadzijusufovich E, Schernthaner G-H, et al. Vascular safety issues in CML patients treated with BCR/ABL 1 kinase inhibitors. Blood. 2015;125(6):901–6. doi: 10.1182/blood-2014-09-594432.
  33. Valent P. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Hematologica. 2011;96(10):1395–7.
  34. Всероссийское научное общество кардиологов. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, IV пересмотр. М., 2009. [Russian Scientific Cardiologists’ Society. Diagnosis and treatment of lipid metabolism impairment for prevention and treatment of atherosclerosis. National Guidelines, IV edition. Moscow; 2009. (In Russ)]
  35. Gardner AW, Poehlman ET. Exercise rehabilitation program for the treatment of claudication pain. A meta-analysis. 1995;274(12):975–80. doi: 10.1001/jama.1995.03530120067043.
  36. Tasigna [prescribing Information]. East Hanover, NJ: Novartis Pharmaceutical Corp.; 2015. [Internet] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022068s0211bl.pdf (accessed 15.06.2016).
  37. Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of а phase 3 study. Blood. 2014;123(15):2317–24. doi: 10.1182/blood-2013-10-532341.
  38. Shah NP, Cortes JE, Schiffer CA, et al. Four-year follow-up patients with chronic myeloid leukemia receiving 100 mg of dasatinib once daily. J Сlin Oncol. 2010;28(Suppl): Abstract
  39. Гусарова Г.А., Туркина А.Г., Воронцова А.В. и др. Отдаленные результаты терапии дазатинибом и анализ особенностей течения плеврального выпота у больных в поздней хронической фазе хронического миелолейкоза после неудачи лечения иматинибом. Бюллетень СО РАМН. 2014;34(6):27–35. [Gusarova GA, Turkina AG, Vorontsova AV, et al. Long-term results of therapy by dasatinib and features analysis of the pleural effusion course in patients at late chronic phase of chronic myeloid leukemia after imatinib treatment failure. Byulleten’ SO RAMN. 2014;34(6):27–35. (In Russ)]
  40. Quintas-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25(25):3908–14. doi: 1200/jco.2007.12.0329.
  41. Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009;43(12):967–8. doi: 10.1038/bmt.2008.415.
  42. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res. 2009;33(6):861–4. doi: 10.1016/j.leukres.2008.09.026.
  43. Dumitrescu D, Seck C, Ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2011;38(1):218–20. doi: 10.1183/09031936.00154210.
  44. Hennigs JK, Keller G, Baumann HJ, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med. 2011;11(1):30. doi: 10.1186/1471-2466-11-30.
  45. Philibert L, Cazorla C, Peyriere H, et al. Pulmonary arterial hypertension induced by dasatinib: positive reintroduction with nilotinib. Fund Clin Pharmacol. 2011;25:95.
  46. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res. 2012;36(1):e4–e6. doi: 10.1016/j.leukres.2011.08.007.
  47. Sano M, Saotome M, Urushida T, et al. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia: critical alert. Intern Med. 2012;51(17):2337–40. doi: 10.2169/internalmedicine.51.7472.
  48. Groeneveldt JA, Gans SJM, Bogaard HJ, Vonk-Noordegraaf A. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. Eur Respir J. 2013;42(3):869–70. doi: 10.1183/09031936.00035913.
  49. Kim JC, Shin SH, Yi HG, et al. Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated dasatinib. Herz. 2013;38(8):931–3. doi: 10.1007/s00059-013-3765-7.
  50. Patkowska E, Lech-Maranda E, Darocha S, et al. Reversible pulmonary arterial hypertension as a complication of dasatinib treatment, with efficacious and safe continuation of chronic myeloid leukaemia therapy with nilotinib. Hematologica. 2013;4(1):76–83.
  51. Buchelli Ramirez HL, Alvarez Alvarez CM, Rodriguez Reguero JJ, et al. Reversible pre-capillary pulmonary hypertension due to dasatinib. Respir Care. 2014;59(5):e77–e80. doi: 10.4187/respcare.02692.
  52. Khaid M, Hakemi E. Concominant development of pleural effusion and pulmonary arterial hypertension in a patient treated with dasatinib. Chest. 2014;146(4):893A. doi: 10.1378/chest.1995250.
  53. Tacoy G, Cengel A, Ozkurt ZN, et al. Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. Turk Dern Ars. 2015;43(1):78–81. doi: 10.5543/tkda.2015.41763.
  54. Wang HC, Lee CS, Liu TC. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography. Kaohsiung J Med Sci. 2015;31(3):165–6. doi: 10.1016/j.kjms.2014.11.010.
  55. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–37. doi: 10.1161/circulationaha.111.079921.
  56. Saglio G, Le Coutre P, Cortes J, et al. Safety and tolerability of dasatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL), pooled analysis of over 2400 patients. Poster presented at: The 19th Congress of the European Hematology Association (EHA) Annual Meeting; June 12–15, 2014; Milan, Italy.
  57. Simmonneau G, Robbins I, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1):43–4. doi: 10.1016/j.jacc.2009.04.012.
  58. Shah NP, Wallis N, Farber HW. Clinical feature of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90(11):1060–4. doi: 10.1002/ajh.24174.
  59. US Food and Drug Administration. FDA Adverse Event Reporting System. US Food and Drug Administration, Silver Spring, MD. [Internet] Available from: http://www.fda.gov/cder/aers/default.htm (accessed 10.04.2015).
  60. Hoeper MM, Barst RJ, Bourge, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMP RES study. Circulation. 2013;127(10):1128–38. doi: 10.1161/circulationaha.112.000765.
  61. Novartis Efficacy, safety, tolerability and pharmacokinetics (pk) of nilotinib (AMN 107) in pulmonary arterial hypertension (PAH). [Internet] Available from: http://clinicaltrials.gov/ct2/show/NCT01179737 (accessed 20.04.2015).
  62. Al-Naamani N, Roberts KE, Hill NS, Preston IR. Imatinib as rescue therapy in a patient with pulmonary hypertension associated with Gaucher disease. Chest. 2014;146(3):e81– doi: 10.1378/chest.13-2795.
  63. Galie N, Humbert M, Vachiery J-L, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2015;37(1):67– doi: 10.1093/eurheartj/ehv317.
  64. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2015. [Internet] Available from: http://packageinserts.bms.com/pi/pi_sprycel.pdf (accessed 15.06.2016).
  65. Садыкова Д.И. Современные подходы к диагностике и лечению легочной гипертензии. Практическая медицина. 2012;7(62):21–6. [Sadykova DI. Modern approaches to diagnostic and treatment of pulmonary hypertension. Prakticheskaya meditsina. 2012;7(62):21–6. (In Russ)]
  66. Godinas L, Guingabert C, Seferian A, et al. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Semin Respir Crit Care Med. 2013;34(5):714–24. doi: 10.1055/s-0033-1356494.
  67. Galie N, Hoeper M, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the ECS and ERS, endorsed by the ISHLT. Eur Heart J. 2009;30(20):2493–537. doi: 1093/eurheartj/ehp297.